Medications as asthma triggers

      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Immunology and Allergy Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hunt L.W.
        • Rosenow III, E.C.
        Asthma-producing drugs.
        Ann Allergy. 1992; 68: 453-462
        • Van Schoor J.
        • Joos G.F.
        • Pauwels R.A.
        Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research.
        Eur Respir J. 2000; 16: 514-533
        • Roberts II, L.J.
        • Morrow J.D.
        Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout.
        in: Hardman J.G. Limbird L.E. Gilman A.G. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York2001: 687-688
        • Widal F.
        • Abrami P.
        • Lermoyez J.
        First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria).
        Presse Med. 1922; 18: 189-192
        • Samter M.
        • Beers R.F.J.
        Intolerance to aspirin: clinical studies and consideration of its pathogenesis.
        Ann Intern Med. 1968; 68: 975-983
        • Kupczyk M.
        • Kuprys I.
        • Gorski P.
        • et al.
        Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma.
        Ann Allergy Asthma Immunol. 2004; 92: 453-458
        • Vally H.
        • Taylor M.L.
        • Thompson P.J.
        The prevalence of aspirin tolerant asthma (AIA) in Australian asthmatic patients.
        Thorax. 2002; 57: 569-574
        • Picado C.
        • Castillo J.A.
        • Montserrat J.M.
        • et al.
        Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation.
        Eur Respir J. 1989; 2: 127-129
        • Marquette C.H.
        • Saulnier F.
        • Leroy O.
        • et al.
        Long-term prognosis of near-fatal asthma.
        Am Rev Respir Dis. 1992; 146: 76-81
        • Jenkins C.
        • Costello J.
        • Hodge L.
        Systematic review of prevalence of aspirin-induced asthma and its implications for clinical practice.
        BMJ. 2004; 328: 434-440
        • Namazy J.A.
        • Simon R.A.
        Sensitivity to nonsteroidal anti-inflammatory drugs.
        Ann Allergy Asthma Immunol. 2002; 89: 542-550
        • Pang L.
        • Pitt A.
        • Petkova D.
        • et al.
        The COX-1/COX-2 balance in asthma.
        Clin Exp Allergy. 1998; 28: 1050-1058
        • Vane J.R.
        Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.
        Nature. 1971; 231: 232-235
        • Pavord I.D.
        Bronchoprotective role for endogenous prostaglandin E2.
        Lancet. 1994; 345: 436-438
        • Kumlin M.
        • Dahlen B.
        • Bjorck T.
        • et al.
        Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics.
        Am Rev Respir Dis. 1992; 146: 96-103
        • Christie P.E.
        • Tagari P.
        • Ford-Hutchinson A.W.
        • et al.
        Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects.
        Am Rev Respir Dis. 1991; 143: 1025-1029
        • Higashi N.
        • Taniguchi M.
        • Mita H.
        • et al.
        Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis.
        J Allergy Clin Immunol. 2004; 113: 277-283
        • Sladek K.
        • Szczeklik A.
        Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.
        Eur Respir J. 1993; 6: 391-399
        • Sladek K.
        • Dworski R.
        • Soja J.
        • et al.
        Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.
        Am J Respir Crit Care Med. 1994; 149: 940-946
        • Szczeklik A.
        • Sladek K.
        • Dworski R.
        • et al.
        Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics.
        Am J Respir Crit Care Med. 1996; 154: 1608-1614
        • Bosso J.V.
        • Schwartz L.B.
        • Stevenson D.D.
        Tryptase and histamine release during aspirin-induced respiratory reactions.
        J Allergy Clin Immunol. 1991; 88: 830-837
        • Cowburn A.S.
        • Sladek K.
        • Soja J.
        • et al.
        Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.
        J Clin Invest. 1998; 101: 834-846
        • Sanak M.
        • Simon H.-U.
        • Szczeklik A.
        Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.
        Lancet. 1997; 350: 1599-1600
        • Penrose J.F.
        • Spector J.
        • Baldasaro M.
        • et al.
        Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35.
        J Biol Chem. 1996; 271: 11356-11361
        • Kedda M.-A.
        • Shi J.
        • Duffy D.
        • et al.
        Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma.
        J Allergy Clin Immunol. 2004; 113: 889-895
        • Kawagishi Y.
        • Mita H.
        • Taniguchi M.
        • et al.
        Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma.
        J Allergy Clin Immunol. 2002; 109: 936-942
        • Van Sambeck R.
        • Stevenson D.D.
        • Baldasaro M.
        • et al.
        5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate wth the aspirin-intolerant asthma phenotype in the United States.
        J Allergy Clin Immunol. 2000; 106: 72-76
        • Stevenson D.D.
        • Sanchez-Borges M.
        • Szczeklik A.
        Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes.
        Ann Allergy Asthma Immunol. 2001; 87: 177-180
        • Szczeklik A.
        • Nizankowska E.
        • Duplaga M.
        Natural history of aspirin-induced asthma.
        Eur Respir J. 2000; 16: 432-436
        • Berges-Gimeno M.P.
        • Simon R.A.
        • Stevenson D.D.
        The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
        Ann Allergy Asthma Immunol. 2002; 89: 474-478
        • Melillo E.
        • Balzano G.
        • Bianco S.
        • et al.
        Report of the INTERASMA Working Group on standardization of inhalation provocation tests in aspirin-induced asthma: oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma.
        Allergy. 2001; 56: 899-911
        • Nizankowska E.
        • Bestynska-Krypel A.
        • Cmiel A.
        • et al.
        Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma.
        Eur Respir J. 2000; 15: 863-869
        • Stevenson D.D.
        • Simon R.A.
        • Zuraw B.L.
        Sensitivity to aspirin and nonsteroidal antiinflammatory drugs.
        in: Middleton E. Reed C. Ellis E. Adkinson N.F. Yunginger J.W. Busse W.W. Bochner B. Simons F.E. Allergy principles & practice. Mosby, St. Louis (MO)2001: 1695-1710
        • Dahlen B.
        • Nizankowska E.
        • Szczeklik A.
        • et al.
        Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
        Am J Respir Crit Care Med. 1998; 157: 1187-1194
        • Dahlen S.-E.
        • Malmstrom K.
        • Nizankowska E.
        • et al.
        Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist.
        Am J Respir Crit Care Med. 2002; 165: 9-14
        • Hosemann W.
        Surgical treatment of nasal polyposis in patient with aspirin intolerance.
        Thorax. 2000; 55: S87-S90
        • Stevenson D.D.
        Approach to the patient with a history of adverse reactions to aspirin or NSAIDs: diagnosis and treatment.
        Allergy Asthma Proc. 2000; 21: 25-31
        • Szczeklik A.
        • Gryglewski R.J.
        • Czerniawska-Mysik G.
        Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis.
        J Allergy Clin Immunol. 1977; 60: 276-284
        • Stevenson D.D.
        • Hougham A.
        • Schrank P.
        • et al.
        Salsalate cross-sensitivity in aspirin-sensitive patients with asthma.
        J Allergy Clin Immunol. 1990; 86: 749-758
        • Kosnik M.
        • Music E.
        • Matjaz F.
        • et al.
        Relative safety of meloxicam in NSAID-intolerant patients.
        Allergy. 1998; 53: 1231-1233
        • Andri L.
        • Senna G.
        • Betteli C.
        • et al.
        Tolerability of nimesulide in aspirin-sensitive patients.
        Ann Allergy. 1994; 72: 29-32
        • Dahlen B.
        • Szczeklik A.
        • Murray J.J.
        Celecoxib in patients with asthma and aspirin intolerance.
        N Engl J Med. 2001; 344: 142
        • Settipane R.A.
        • Schrank P.
        • Simon R.A.
        • et al.
        Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects.
        J Allergy Clin Immunol. 1995; 96: 480-485
        • Gyllfors P.
        • Bochenek G.
        • Overholt J.
        • et al.
        Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
        J Allergy Clin Immunol. 2003; 111: 1116-1121
        • Martin-Garcia C.
        • Hinojosa M.
        • Berges P.
        • et al.
        Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
        Chest. 2002; 121: 1812-1817
        • Stevenson D.D.
        • Simon R.A.
        Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
        J Allergy Clin Immunol. 2001; 108: 47-51
        • Sanchez-Borges M.
        • Capriles-Hulett A.
        • Caballero-Fonsenca F.
        • et al.
        Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.
        Ann Allergy Asthma Immunol. 2001; 87: 201-204
        • Schellenberg R.R.
        • Isserow S.H.
        Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor.
        N Engl J Med. 2001; 345: 1856
        • Stevenson D.D.
        • Simon R.A.
        • Mathison D.A.
        Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges.
        J Allergy Clin Immunol. 1980; 66: 82-88
        • Pleskow W.W.
        • Stevenson D.D.
        • Mathison D.A.
        • et al.
        Aspirin desensitization in aspirin sensitive asthmatic patients: clinical manifestations and characterization of the refractory period.
        J Allergy Clin Immunol. 1982; 69: 11-19
        • Berges-Gimeno M.P.
        • Simon R.A.
        • Stevenson D.D.
        Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.
        J Allergy Clin Immunol. 2003; 111: 180-186
        • Sweet J.M.
        • Stevenson D.D.
        • Simon R.A.
        • et al.
        Long-term effects of aspirin desensitization: treatment for aspirin-sensitive rhinosinusitis-asthma.
        J Allergy Clin Immunol. 1990; 85: 59-65
        • Stevenson D.D.
        • Hankammer M.A.
        • Mathison D.A.
        • et al.
        Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes.
        J Allergy Clin Immunol. 1996; 98: 751-758
        • Nasser S.M.
        • Patel M.
        • Bell G.S.
        • et al.
        The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma.
        Am J Respir Crit Care Med. 1995; 151: 1326-1330
        • Juergens U.R.
        • Christiansen S.C.
        • Stevenson D.D.
        • et al.
        Inhibition of monocyte leukotriene B4 production following aspirin desensitization.
        J Allergy Clin Immunol. 1995; 96: 148-156
        • Krumholz H.M.
        • Radford M.J.
        • Wang Y.M.S.
        • et al.
        National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project.
        JAMA. 1998; 280: 623-629
        • Okayama M.
        • Yafuso N.
        • Nogami H.
        • et al.
        A new method of inhalation challenge with propranolol: comparison with methacholine-induced bronchoconstriction and role of vagal nerve activity.
        J Allergy Clin Immunol. 1987; 80: 291-299
        • Zaid G.
        • Beall G.N.
        Bronchial response to beta-adrenergic blockade.
        N Engl J Med. 1966; 275: 580-584
        • Barnes P.J.
        Neural control of human airways in health and disease.
        Am Rev Respir Dis. 1986; 134: 1289-1314
        • Ind P.W.
        • Dixon C.M.
        • Fuller R.W.
        • et al.
        Anticholinergic blockade of beta-blocker-induced bronchoconstriction.
        Am Rev Respir Dis. 1989; 139: 1390-1394
        • Okayama M.
        • Shen T.
        • Midorikawa J.
        • et al.
        Effect of Pilocarpine on propranolol-induced bronchoconstriction in asthma.
        Am J Respir Crit Care Med. 1994; 149: 76-80
        • Crimi N.
        • Palermo F.
        • Oliveri R.
        • et al.
        Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction.
        J Allergy Clin Immunol. 1988; 82: 617-621
        • Koeter G.H.
        • Meurs H.
        • De Monchy J.G.
        • et al.
        Protective effect of disodium cromoglycate on propranolol challenge.
        Allergy. 1982; 37: 587-590
        • Foresi A.
        • Chetta A.
        • Pelucchi A.
        • et al.
        Effect of inhaled disodium cromoglycate and nedocromil sodium on propranolol-induced bronchoconstriction.
        Ann Allergy. 1993; 70: 159-163
        • Fujimura M.
        • Abo M.
        • Kamio Y.
        • et al.
        Effect of leukotriene and thromboxane antagoinist on propranolol-induced bronchoconstriction.
        Am J Respir Crit Care Med. 1999; 160: 2100-2103
        • Ind P.W.
        • Barnes P.J.
        • Brown M.J.
        • et al.
        Plasma histamine concentration during propranolol induced bronchoconstriction.
        Thorax. 1985; 40: 903-909
        • Emilien G.
        • Maloteaux J.-M.
        Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists.
        Eur J Clin Pharmacol. 1998; 53: 389-404
        • Boskabady M.H.
        • Snashall P.D.
        Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta-blockade in asthma.
        Respirology. 2000; 5: 111-118
        • Carstairs J.R.
        • Nimmo A.J.
        • Barnes P.J.
        Autoradiogaphic visualization of beta-adrenoceptor subtypes in human lung.
        Am Rev Respir Dis. 1985; 132: 541-547
        • Spina D.
        • Rigby P.J.
        • Paterson J.W.
        • et al.
        Autoradiographic localization of beta-adrenoceptors in asthmatic human lung.
        Am Rev Respir Dis. 1989; 140: 1410-1415
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
        Hypertension. 2003; 42: 1206-1252
        • Schoene R.B.
        • Martin T.R.
        • Charan N.B.
        • et al.
        Timolol-induced bronchospasm in asthmatic bronchitis.
        JAMA. 1981; 245: 1460-1461
      1. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol 1997;80:15J–9.

        • Wood A.J.
        Pharmacologic differences between beta blockers.
        Am Heart J. 1984; 108: 1070-1077
        • Hoffman B.B.
        Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists.
        in: Hardman J.G. Limbird L.E. Gilman A.G. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York2001: 215-253
        • Salpeter S.R.
        • Ormiston T.M.
        • Salpeter E.E.
        Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis.
        Ann Intern Med. 2002; 137: 715-725
        • Dunn T.L.
        • Gerber M.J.
        • Shen A.S.
        • et al.
        The effect of topical ophthalmic instillation of Timolol and Betaxolol on lung function in asthmatic subjects.
        Am Rev Respir Dis. 1986; 133: 264-268
        • Fraunfelder F.T.
        • Barker A.F.
        Respiratory effects of Timolol.
        N Engl J Med. 1984; 311: 1441
        • Cazzola M.
        • Noschese P.
        • D'Amato G.
        • et al.
        Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.
        Chest. 2000; 118: 1322-1326
        • National Asthma Education and Prevention Program
        Expert Panel Report II. Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute/National Institute of Health, Bethesda1997
        • Shulan D.J.
        • Katlan M.
        Use of β-blockers in patients with reactive airway disease.
        Ann Intern Med. 2003; 139: 304
        • Gottlieb S.S.
        • McCarter R.J.
        • Vogel R.A.
        Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.
        N Engl J Med. 1998; 339: 489-497
        • Ryan T.J.
        • Antman E.M.
        • Brooks N.H.
        • et al.
        1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations.
        Circulation. 1999; 100: 1016-1030
        • Mohammad J.T.
        • Weinacker A.B.
        Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma.
        Pharmacotherapy. 1999; 19: 974-978
        • Piepho R.W.
        Role of angiotensin-converting-enzyme inhibition in contemporary cardiovascular therapy.
        Am J Health Syst Pharm. 2000; 57: S2
        • Israili Z.H.
        • Hall W.D.
        Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy.
        Ann Intern Med. 1992; 117: 234-242
        • Schaefer B.M.
        • Caracciolo V.
        • Frishman W.H.
        • et al.
        Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy.
        Heart Dis. 2003; 5: 202-214
        • Simon S.R.
        • Black H.R.
        • Moser M.
        • et al.
        Cough and ACE inhibitors.
        Arch Intern Med. 1992; 152: 1698-1700
        • Goldszer R.C.
        • Lilly L.S.
        • Solomon H.S.
        Prevalence of cough during angiotensin-converting enzyme inhibitor therapy.
        Am J Med. 1988; 85: 887
        • Just P.M.
        The positive association of cough with angiotensin-converting enzyme inhibitors.
        Pharmacotherapy. 1989; 9: 82-87
        • Wood R.
        Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril: a controlled retrospective cohort study.
        Br J Clin Pharmacol. 1995; 39: 265-270
        • Kaufman J.
        • Schmitt S.
        • Barnard J.
        • et al.
        Angiotensin-coverting enzyme inhibitors in patients with bronchial responsiveness and asthma.
        Chest. 1992; 101: 922-925
        • Craig T.J.
        Drugs to be used with caution in patients with asthma.
        Am Fam Physician. 1996; 54: 947-953
        • Peacock A.J.
        • Matthews A.W.
        The effect of captorpril on pulmonary haemodynamics and lung function in patients with chronic airflow obstruction.
        Thorax. 1986; 41: 225
        • Dixon C.M.
        • Fuller R.W.
        • Barnes P.J.
        The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects.
        Br J Clin Pharmacol. 1987; 23: 91-93
        • Boulet L.-P.
        • Milot J.
        • Lampron N.
        • et al.
        Pulmonary function and airway responsiveness during long-term therapy with captopril.
        JAMA. 1989; 261: 413-416
        • Popa V.
        Captopril-related (and -induced?) asthma.
        Am Rev Respir Dis. 1987; 136: 999-1000
        • Semple P.F.
        • Herd G.W.
        Cough and wheeze caused by inhibitors of angiotensin-converting enzyme.
        N Engl J Med. 1986; 314: 61
        • Brown N.J.
        • Vaughan D.E.
        Angiotensin-converting enzyme inhibitors.
        Circulation. 1998; 97: 1411-1420
        • Os I.
        • Bratland B.
        • Dahlof B.
        • et al.
        Female sex as an important determinant of lisinopril-induced cough.
        Lancet. 1992; 339: 372
        • Gibson G.R.
        Enalapril-induced cough.
        Arch Intern Med. 1989; 149: 2701-2703
        • Kawakami Y.
        • Munakata M.
        • Yamaguchi E.
        • et al.
        Molecular studies of bronchial asthma, sarcoidosis and angiotensin converting enzyme inhibitor-induced cough.
        Respirology. 1998; 3: 45-49
        • Dart R.A.
        • Gollub S.
        • Lazar J.
        • et al.
        Treatment of systemic hypertension in patients with pulmonary disease.
        Chest. 2003; 123: 222-243
        • Fuller R.W.
        • Choudry N.B.
        Increased cough reflex associated with angiotensin converting enzyme inhibitor cough.
        BMJ. 1987; 295: 1025-1026
        • Buck S.H.
        • Burks T.F.
        Capsaicin: hot new pharmacological tool.
        Trends Pharmacol Sci. 1983; 4: 84-87
        • McEwan J.R.
        • Fuller R.W.
        Angiotensin converting enzyme inhibitors and cough.
        J Cardiovasc Pharmacol. 1989; 13: S67-S69
        • Nicholls M.G.
        • Gilchrist N.L.
        Sulindac and cough induced by converting enzyme inhibitors.
        Lancet. 1987; I: 872
        • Fuller R.W.
        • McEwan J.R.
        • Choudry N.B.
        The abnormal cough reflex: role of prostaglandins.
        Am Rev Respir Dis. 1989; 139: A586
        • Fuller R.W.
        • Dixon C.M.
        • Cuss F.M.
        • et al.
        Bradykinin-induced bronchoconstriction in humans.
        Am Rev Respir Dis. 1987; 135: 176-180
        • Varonier H.S.
        • Panzani R.
        The effect of inhalations of bradykinin on healthy and atopic (asthmatic) children.
        Int Arch Allergy. 1968; 34: 293-296
        • Polosa R.
        • Phillips G.D.
        • Lai C.K.
        • et al.
        Contribution of histamine and prostanoids to bronchoconstriction provoked by inhaled bradykinin in atopic asthma.
        Allergy. 1990; 45: 174-182
        • Cazzola M.
        • Matera M.G.
        • Liccardi G.
        • et al.
        Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough.
        Respiration (Herrlisheim). 1993; 60: 212-215
        • Hargreaves M.
        Sodium cromoglycate: a remedy for ace inhibitor-induced cough.
        Br J Clin Pract. 1993; 47: 319-320